Investment Pitches

Pitch Summary:
The largest contributor was SDCL Energy Efficiency Income (SEIT), an investment company focussed on energy efficiency and decentralised energy generation projects. We wrote on SEIT in last month’s newsletter. While SEIT typically appears alongside renewable energy funds in broker lists and AIC publications, its assets have different characteristics from those of this peer group. In contrast to peers, SEIT has very limited exposure to power price risk, and the platform nature of its investments allows for active management and investment to drive higher returns. Being in a true peer group of one has its disadvantages, however, and the added complexity of its portfolio has meant that its shares have traded at a wider discount than renewable energy focussed investment companies. In response, SEIT has adopted the same playbook as other funds in the broader alternative asset sector: sell assets (and in doing so prove out carrying values), pay down short-term debt, and buy back shares. Notwithstanding the sale of a solar portfolio last year above carrying value, this has proved harder to achieve in practice against a backdrop of deferred central bank interest rate cuts and macroeconomic and geopolitical instability. Reported strong interest in SEIT’s largest asset, Onyx, fell away in the wake of the risk aversion triggered by “Liberation Day”, and the revised plan for this asset is to now bring on board equity co-investors instead. SEIT’s share price had already begun recovering by the time its results were released in late-June, but comments from the Chair that “the status quo is clearly unsustainable and so the Board is considering all strategic options to deliver value for all shareholders in an effective and efficient manner” gave an additional boost to the share price which ended June up +28% over the month, leaving the shares trading on a 39% discount to estimated NAV.

BSD Analysis:
SDCL invests in the most underrated part of the energy transition: efficiency. These are behind-the-meter, contracted, yield-heavy assets — CHP systems, HVAC optimization, industrial energy savings — that deliver guaranteed cost reductions to customers. The cash flows are stable, inflation-linked, and uncorrelated with commodity prices. It’s basically a private-infrastructure portfolio wrapped in a listed trust, trading at a discount because investors chase sexier themes. Efficiency is the lowest-risk megatrend in energy, and SDCL sits right on top of it.

Pitch Summary:
Air Liquide contributed positively in Q2 as the company benefited from resilient industrial demand and growth in hydrogen and electronics-related gases. Management highlighted margin expansion from pricing actions and efficiency programs. The company continues to invest in energy transition infrastructure, including large-scale electrolyzer projects.

BSD Analysis:
Air Liquide is the industrial-gas giant positioned squarely at the convergence of clean energy, semiconductors, healthcare, and advanced manufacturing. Its long-term contracts and pricing mechanisms make it one of the most resilient industrial businesses on Earth. Hydrogen, electronics gases, and medical oxygen provide secular growth, while scale and infrastructure create a moat miles deep. This is a quiet compounder with infrastructure-like predictability and tech-like tailwinds.

Pitch Summary:
Argenx detracted in Q2 following weaker-than-expected demand for Vyvgart, its flagship therapy for generalized myasthenia gravis. Management cited slower new patient starts and competitive pressures. The company lowered full-year guidance and noted rising operating expenses tied to commercialization and pipeline investments. Investors reacted negatively to the reduced visibility and uncertain trajectory for Vyvgart.

BSD Analysis:
argenx is one of biotech’s modern success stories — an immunology pure-play turning antibody innovation into real commercial traction. Vyvgart is scaling globally and expanding across multiple indications, with subcutaneous and chronic-dosing opportunities building a franchise worth far more than the market credits. The pipeline is deep, the tech platform is validated, and execution has been stellar. argenx is a high-quality biotech that behaves like a future megacap.

Pitch Summary:
Medacta delivered strong Q2 results, with double-digit revenue growth driven by implant demand in hip and knee procedures. The company’s patient-specific instrumentation and surgeon training programs continued to differentiate its offering in a competitive market. Margins expanded thanks to operating leverage and cost efficiencies. Management raised guidance and highlighted continued global penetration opportunities.

BSD Analysis:
Medacta is a high-growth orthopedics company with a differentiated surgeon-focused model and strong momentum in hips, knees, and spine. Its minimally invasive technologies and personalized implants are winning share, and Medacta’s global expansion remains early in its trajectory. Orthopedics is a scale business, but Medacta punches above its weight with surgeon loyalty and precision-focused innovation. This is a premium medtech compounder hiding behind small-cap liquidity.

Pitch Summary:
UCB was among our top contributors in Q2. The company reported strong sales of its recently launched immunology and neurology biologics, with revenue up double digits and operating profit growing even faster. Management indicated that uptake for its psoriasis and epilepsy treatments was exceeding expectations, helping offset patent expirations in older products. The company also upgraded its full-year guidance, noting expanding margins due to mix shift toward newer high-value biologics.

BSD Analysis:
UCB is the underappreciated European biotech-pharma hybrid with a seriously potent pipeline in neurology and immunology. New launches like Bimzelx are gaining traction, and multiple late-stage assets give UCB multi-year revenue visibility. The company has reduced its patent-cliff risk and is transitioning into a more diversified, innovation-led model. With clean execution and strong therapeutic niches, UCB is one of Europe’s quietest large-cap growers.

Pitch Summary:
In the machinery industry, our holdings in Mitsubishi Heavy Industries (MHI) and Hyundai Rotem were meaningful contributors to quarterly outperformance. Both companies benefit from two dominant themes currently in the portfolio: electrification and defense infrastructure. MHI manufactures gas turbines that cost over $1 billion and produce large quantities of electricity, as well as equipment such as ships, aircraft and weapon systems used in the defense industry. Hyundai Rotem makes a range of high-speed trains and locomotives, as well as armored recovery vehicles and defense-related equipment. New orders announced in the quarter from Poland, South Korea and Taiwan have raised profit expectations for the company. Sales for Q1 increased 57%, while net income tripled to $112 million.

BSD Analysis:
Hyundai Rotem is riding a boom in armored vehicles, rail infrastructure, and defense exports — all heavily backed by Korean industrial policy. Its K2 tanks, K808 vehicles, and rail solutions continue winning orders from Europe, Asia, and the Middle East. With geopolitical risk rising globally, Rotem sits at the intersection of both defense ramp-ups and green transportation upgrades. The backlog is massive, margins are improving, and export demand remains white-hot.

Pitch Summary:
In the machinery industry, our holdings in Mitsubishi Heavy Industries (MHI) and Hyundai Rotem were meaningful contributors to quarterly outperformance. Both companies benefit from two dominant themes currently in the portfolio: electrification and defense infrastructure. MHI manufactures gas turbines that cost over $1 billion and produce large quantities of electricity, as well as equipment such as ships, aircraft and weapon systems used in the defense industry. Hyundai Rotem makes a range of high-speed trains and locomotives, as well as armored recovery vehicles and defense-related equipment. New orders announced in the quarter from Poland, South Korea and Taiwan have raised profit expectations for the company. Sales for Q1 increased 57%, while net income tripled to $112 million.

BSD Analysis:
MHI is a Japanese industrial titan perfectly positioned for the global trifecta: rearmament, energy transition, and aerospace recovery. Defense orders are hitting multi-decade highs, turbine demand is rebounding, and hydrogen/ammonia infrastructure puts MHI at the center of decarbonization. Years of restructuring built a leaner business that now benefits from enormous tailwinds. This is a global industrial powerhouse investors still treat like an old conglomerate — a mistake.

Pitch Summary:
While international markets delivered robust returns, the portfolio outperformed the MSCI EAFE Index and delivered another strong quarter of performance. Relative results were led by stock selections across multiple themes, sectors and industries. Industrials were a standout contributor with stocks ranging from aerospace and defense, machinery, electrical equipment and airlines among the numerous double-digit gainers during the quarter. Many of these holdings reflect the teams’ preference for quality growth stocks in the infrastructure and electrification themes that we have highlighted in past quarters. Aerospace and defense industry holdings in South Korea (LIG Nex1 and Hanwha Aerospace) and in Europe (Babcock International, Melrose and Airbus) delivered exceptional returns on the back of strong earnings and order books. The gains arose from an expected spending increase on defense-related infrastructure, validated in late June when NATO countries agreed to raise their spending to 5% of GDP over the next 10 years. Babcock International, for example, reported full-year results for the year ended March that showed 11% organic growth in sales to £4.8 billion and a rise in profits to £247 million from £165 million a year ago. The company boosted its dividend by 30%, announced a 200 million share buyback and raised its medium-term guidance on operating margins to at least 9% based on expectations of a “new era” in defense-related spending.

BSD Analysis:
Babcock is a defense and engineering contractor that finally got its house in order after years of chaos. Now the fundamentals actually match the quality of its niche: naval support, nuclear maintenance, and mission-critical engineering. Global rearmament cycles are strengthening backlog, management has restored discipline, and margins are improving off a beaten-down base. This is a turnaround with structural tailwinds behind it — a far better setup than the stock price implies.

Pitch Summary:
Vulcan Materials is the second-largest aggregates company in the Americas, selling 224 million tons of aggregates in 2024 with 16.5 billion tons of proven and probable reserves. Its nationwide network of 423 active facilities creates scale advantages, lower delivered costs, and superior reliability versus smaller competitors. Like peers, Vulcan benefits from strong barriers to entry due to NIMBY-driven permitting difficulty, consolidation, and aggregates’ extremely low value-to-weight economics that localize markets. Furthermore, aggregates prices have risen steadily for decades with limited cyclicality, even during severe downturns such as 2006–2010. Demand across residential, commercial, and infrastructure sectors is structurally under-supplied, with housing shortages, industrial onshoring, and decades of infrastructure underinvestment all supporting long-term volume growth. These dynamics create a compelling setup for Vulcan to raise prices above inflation, expand margins, and acquire smaller operators to deepen local market dominance.

BSD Analysis:
YCG argues Vulcan is a high-quality toll collector on U.S. construction activity, with durable competitive moats from network scale, permitting scarcity, and localized market power. The stock benefits from inflation-resistant pricing and stable through-cycle economics despite volume cyclicality. Long-term catalysts include housing undersupply, industrial reshoring, and infrastructure spending that should lift demand above long-term averages. With strong balance sheet discipline and accretive M&A potential, Vulcan can compound free cash flow while maintaining market leadership. Near-term recession fears may depress valuation but do not impair the long-term thesis.

Pitch Summary:
We also invested 2% in AJ Bell in May, investing some of the cash, following our reduction of NEXT plc. AJ Bell operates a capital-light, high-return model. It has delivered strong incremental cash returns on gross equity over the last five years of 71% and continues to grow organically, benefitting from demographic and regulatory tailwinds (e.g. pension freedoms, ageing population). Assets under administration (AUA) and customer numbers have both grown meaningfully since the 2019 IPO. AJ Bell’s business is underpinned by high customer satisfaction and a retention rate of ~94%. It combines low prices with good service, supported by scalable technology (e.g. ‘Touch’ platform for advisers). Culturally, the company echoes Admiral in its employee ownership and purpose-led values, which we like! Culture & Leadership: Culture is a key driver of long-term value. Employees received share grants at IPO and the internal values (Straightforward, Intelligent, Personal, Principled, Energetic) are well embedded in its business. Leadership is strong—CEO Michael Summersgill has risen internally and maintains the cultural continuity post the departure of the founder, Andy Bell, in 2022. Financial Resilience & Valuation: Revenue is split between fixed, ad valorem and transactional fees, giving balance and inflation protection. The company has no debt (outside lease liabilities) and is conservatively financed. The valuation, stands at ~21.5x trailing Price/Earnings (vs 33x average), with 22% annual EPS growth since IPO and a 31% net margin feeding into strong returns on capital and equity. Risks & Competition: Risks include the competitive response from Hargreaves Lansdown under new ownership (CVC) and the normalisation of net interest income as rates stabilise. However, the long-term structural growth drivers remain intact for AJ Bell’s investment case.

BSD Analysis:
The manager clearly positions AJ Bell as a high-return, culture-strong compounder benefiting from structural tailwinds in pensions and savings, with a scalable platform and conservative balance sheet. In their view, the combination of high customer retention, strong brand in both advised and direct-to-consumer channels and disciplined capital allocation supports a long runway for double-digit earnings growth. At a discount to its historical multiple despite robust fundamentals, AJ Bell offers an appealing blend of quality, growth and reasonable valuation within the UK financials universe.

Pitch Summary:
In April we invested 2% in Greggs PLC. The investment case for Greggs is centred on Branding and Process Power - built on its strong brand recognition, consistent financial performance and strategic growth initiatives. The company has demonstrated resilience in its operations, with a focus on expanding its market presence and enhancing customer experience, which positions it well for future growth. Greggs' moat includes its strong brand loyalty reflected in its extensive network of stores and established supply chain. The company’s commitment to quality and customer service further strengthens its competitive advantage. Following the impact of Covid, its developing relationships with Uber Eats and Just Eat, provides greater distribution resilience – were another type of ‘lock-down’ to occur. Greggs' Revenue pathway is driven by expanding its store footprint, enhancing product offerings and increasing sales through delivery and online channels. The company aims to grow its customer base and improve sales per store through innovation and marketing strategies. There has been lots of evidence of its innovation over the years. Its vegan sausage roll, being one such example; and the technological development of a Greggs ‘App’, through which 20% of orders now come. The valuation analysis was impacted by the Covid loss making year of 2020, which blew out the valuation rating due to the impact on earnings. However, we can adjust for this in order to understand the valuation opportunity. Our Reverse Discounted Cash Flow model adjusts for the period of Covid. Greggs have traded on a long run average P/E of 18 years in relation to its earnings. Today the valuation stands at only 12x, which should provide a good potential re-rating, to enhance the investment return as it compounds its return on invested capital. It appears that the market believes the business has matured, yet it continues to grow and has made investment in further distribution infrastructure. As the store numbers increase towards 3,000 shops in the UK and store opening hours expand across the portfolio of shops - this should enhance incremental returns. There are still many areas in the UK that are underpenetrated by Greggs, providing further room for growth.

BSD Analysis:
The manager sees Greggs as a high-quality, branded food-on-the-go retailer with a long runway in format expansion, digital engagement and delivery, supported by a robust balance sheet and proven execution. A below-average multiple relative to its history, despite continued growth and investment in distribution infrastructure, creates an attractive entry point for a business with solid returns on invested capital. As geographic penetration improves and operating leverage from longer opening hours and higher throughput builds, earnings compounding plus potential multiple expansion could deliver strong shareholder returns.

Pitch Summary:
Croda International is a specialty chemicals manufacturer, supplying ingredients for personal care, pharmaceuticals and crop science. For Croda their switching costs arise from formulation dependency: Many customers—such as cosmetics companies—design their product formulas specifically around Croda’s specialty ‘active’ ingredients. Reformulating to use a competitor’s ingredient can take a long time (new R&D, testing and regulatory clearances). Quality & Reliability Requirements is also another consideration for them. In pharmaceuticals or high-end cosmetics, reliability and consistency of supply are paramount. Once a customer has validated Croda’s inputs for efficacy and safety, switching to something new can jeopardize brand reputation or product efficacy. In short, Croda benefits from high switching costs because its products are tightly integrated into customers’ processes, locked by regulation and supported by long-term partnerships. That is a big part of why Croda’s business model is so resilient. However, it should be noted though that Croda is presently coming through a difficult trading period. Switching costs don’t insulate the business entirely, if end market demand softens. This is what Croda experienced through Covid. Initially, demand for its products rose strongly given end customers concerned over supply chain issues, overstocked. The following period of stock unwinding has been challenging for Croda, but it appears that with demand recovering in China—a major market; and elsewhere, incremental returns should improve this financial year. By analysing the extent to which a company creates high switching costs for its customers, we should be better able to gauge the strength and longevity of a firm’s profitability, notwithstanding cyclical changes to end market demand—as evidenced by Croda International.

BSD Analysis:
Castlebay’s thesis treats Croda’s recent challenges as cyclical rather than structural, with the core franchise underpinned by high-value, formulation-critical ingredients and sticky customer relationships. As inventory destocking abates and end-market demand recovers, operating leverage and pricing power should support margin repair. For long-term investors, the combination of specialised know-how, regulatory barriers and strong customer integration offers an attractive moat in a structurally growing set of end markets.

Pitch Summary:
Intertek is a leading global provider of assurance, testing, inspection and certification (ATIC) services. Much like its peers (SGS or Bureau Veritas), Intertek offers critical validation of product quality, safety and regulatory compliance across a wide range of industries. Its Switching Cost Power manifests in the following ways: 5) Mission-Critical Compliance Regulatory Approvals: Many sectors—such as pharmaceuticals, consumer goods, electronics and food—rely on Intertek to certify that products meet official regulations and safety standards. 6) Cost of Re-Certification: If a manufacturer or distributor switches from Intertek to another TIC provider, they often need to undertake a new round of testing and certification—a time-consuming and expensive process. These re-certification costs (and potential operational delays) raise the switching barriers for customers. 7) Deep Integration in Supply Chains Customised Testing Protocols: Over time, Intertek develops industry or product-specific protocols in partnership with its clients. They learn their customer’s unique processes, formulations or product specifications. 8) Process Familiarity: Once Intertek has established standardised testing methods that integrate with a client’s internal processes (e.g., quality control checks, documentation flows), replacing them means altering workflows and retraining staff. In other words, Intertek’s testing and certification often becomes woven into its clients’ manufacturing and quality-management systems. 9) Trust and Brand Reputation Customer & End-Consumer Assurance: A certification stamp from a reputable TIC firm like Intertek can serve as a recognised mark of safety and quality. Particularly in consumer-facing industries, retailers and end consumers come to trust that seal. 10) Risk of Reputational Damage: Switching to a less-known or unproven certification body can introduce perceived risk. Manufacturers may worry that the new provider’s mark won’t carry the same weight with retailers, regulators or end consumers. This reputational aspect subtly increases switching costs, even if the customer could switch, they might not want to jeopardize brand trust or regulatory perception. 11) Long-Standing Relationships and Framework Agreements Multi-Year Contracts: Large clients often negotiate multi-year service agreements covering a variety of testing services at a global scale. Breaking these agreements or switching midstream can be costly and create supply chain disruptions. Over time, Intertek has become a “preferred supplier” in many corporate procurement databases, ensuring a steady stream of work across geographies. The administrative overhead of onboarding or re-qualifying new testing partners adds friction to switching. Intertek’s Switching-Cost Moat leads to recurring revenues in excess of 90%. We can infer from this that Intertek’s high switching costs protect their business from competition leading to high customer retention rates and relatively stable revenues; all of which support pricing power for Intertek—classic hallmarks of a “Switching Cost” advantage as described by Hamilton Helmer.

BSD Analysis:
The manager frames Intertek as a resilient compounder where high switching costs, mission-critical services and multi-year relationships underpin stable, high-quality cash flows. These characteristics typically support attractive returns on capital and justify a quality premium versus more cyclical industrial names. While macro slowdowns can affect testing volumes at the margin, regulatory complexity, globalised supply chains and rising quality standards should structurally support demand for TIC services, leaving Intertek well positioned for steady, long-term growth.

Pitch Summary:
Several of our businesses exhibit strong switching-cost dynamics in their markets: RELX provides scientific, technical and medical information services, as well as legal and business analytics (e.g., LexisNexis). There is deep integration of RELX’s services in large legal teams, universities and corporate clients - all of which rely on RELX’s services in providing mission-critical data. Switching to another provider means retraining staff, migrating large amounts of historical data and research references; which means potentially losing access to specialised analytics tools. This in turn could cause workflow disruption. In legal or academic research, everything from citation systems to document collaboration integrates heavily with RELX’s platforms, raising the friction of switching to another provider.

BSD Analysis:
The switching-cost dynamics described by Castlebay map onto RELX’s highly recurring, data-driven business model, which has historically delivered strong margins and returns on capital. Deep integration into customer processes and multi-year contracts provide good revenue visibility, while ongoing product innovation in analytics and workflow tools strengthens the moat over time. Although regulatory and budget pressures can periodically weigh on individual segments, the diversified portfolio across risk, STM, legal and exhibitions reduces single-vertical risk and supports a long runway for steady compounding.

Pitch Summary:
North American copper producer and portfolio company Taseko Mines (TGB), delivered strong performance in recent months, driven by rising copper prices and a number of compelling company-specific developments. On June 5th Taseko announced a partial sale of the New Prosperity copper-gold deposit in Canada for $75m. The sale proceeds provides additional liquidity while Taseko retains 77.5 percent ownership, preserving significant cash flow and earnings potential as the project develops over the coming years. Additionally, Taseko is currently in the final stages of bringing the Florence mine in Arizona into production. Management anticipates production to begin in mid-2026, and is expected to nearly double Taseko’s copper output from approximately 120 million pounds in 2025 to roughly 200 million pounds by 2027. The Florence mine will be one of the largest US copper mines to come into production over the past decade. Utilizing an environmentally friendly form of copper recovery called In-Situ Copper Recovery (ISCR), the project is projected to produce 99.99% pure copper cathodes at a low cash cost of $1.25 per pound. With copper prices above $5 per pound today, TGB is well positioned to grow earnings and cash flow in the coming quarters. We believe Taseko trades significantly below its net asset value, based on discounted future cash flows, offering excellent exposure to a fundamentally strong copper market driven by a tight global supply and demand.

BSD Analysis:
Taseko is a pure torque play on copper — exactly what you want if you believe electrification demand will outrun supply. Gibraltar provides stable base output, but the real prize is Florence, a low-cost in-situ copper project with the potential to transform Taseko’s cost structure and free cash flow profile. The market has dragged its feet on valuing Florence due to permitting drama, but those roadblocks are finally clearing, and the economics are compelling: low capital intensity, competitive opex, and a copper price environment leaning structurally tighter. Taseko’s balance sheet is manageable, and the company has shown discipline in not overextending ahead of project de-risking. If copper tightens — and all signs point that way — Taseko could see outsized equity upside with minimal incremental volume growth. This is a levered bet on the coming copper crunch, and it screens cheaper than it should.

Pitch Summary:
We also used the sell-off in April to initiate a new position in Vishay Precision Group (VPG). VPG manufactures precision measurement and sensing technologies used in a variety of end markets including industrial processing, medical, and transportation. Historically, VPG has served niche areas within these end markets which has provided solid profitability but slower growth. However, with the rise of electrification and automation across almost all industries VPG now sees an opportunity to accelerate growth given secular tailwinds. For example, VPG management has highlighted the critical need for VPG sensors in surgical robots as well as the emergence of industrial and general purpose robots. The most notable application would be Tesla’s Optimus robot, which was prototyped in 2022 and is targeting production in 2026. Optimus features human-like dexterity and would allow for humanoid robots to replace humans doing repetitive and dangerous factory work. At the time of purchase, VPG shares were trading at $20 per share ($230m market cap), with $30m in net cash, and trading at 80% of book value. We believe that the aforementioned secular catalysts combined with a cyclical upturn in several of VPG’s end markets sets up VPG to experience accelerated growth over the next several years. Management has laid out a three-to-five year target of double digit top line growth and growing operating margins from 6% at the end of 2024 to mid-to-high teens. If VPG is able to achieve these targets annual EBITDA would be approaching $100m. Using a conservative 6x multiple on $100m EBITDA would value the company at $45-50 per share.

BSD Analysis:
Vishay Precision Group is the kind of niche industrial tech company that quietly embeds itself into high-value applications — aerospace, medical, semiconductor tools — and then compounds for years without anyone noticing. Its sensors, weighing systems, and foil resistors aren’t sexy, but they’re mission-critical, high-margin components customers don’t switch away from unless forced. Supply chain normalization and a more rational capex environment are helping margins recover, while VPG’s balance sheet gives it flexibility to lean into growth projects without risking stability. The company consistently throws off cash and benefits from long product cycles, giving it a level of durability you rarely get in small-cap industrials. The stock trades like a low-growth manufacturing relic, but its premium niches and pricing power tell a different story. As industrial automation and precision measurement demand accelerate, VPG’s multiyear setup looks underappreciated.

Pitch Summary:
World’s largest fuel cell maker; solid oxide tech converts NG/biogas to electricity at ~9–12c/kWh, modular/reliable, lower emissions. Pivoting from niche industrial to AI datacenter power solution amid grid constraints. Author sees 30%+ EPS CAGR, unit sales 1–2 GW by ’27, $2–6 EPS potential, and upside to $60–120/sh mid-term, $200+ longer-term on cost parity and hydrogen optionality. Short interest and ITC expiry weigh on sentiment, but contracts (AEP, Equinix) and exec hires suggest inflection.

BSD Analysis:
Bloom is positioned to benefit from AI-driven power demand, particularly inference DCs needing fast-deployed, local, clean baseload. Its 65–90% efficiency, modularity, and carbon capture advantages make it competitive despite NG reliance. Scaling risk, ITC expiration, and tech disruption (fusion/nuclear/storage) are real, but near-term economics, industrial demand, and AI infrastructure tailwinds are powerful. With limited downside ($20–30 bear case) and asymmetric upside (5–10x over decade if cost parity/hydrogen realized), BE is a compelling GARP/compounder in energy-tech.

Pitch Summary:
China ride-hailing leader regaining share/margins post-probe; core CN mobility guiding to ~4–6% EBITA/GTV by ’26–’27, Intl. narrowing losses (LATAM #2 BR/#1 MX). Valuation ~7x FY27E EBIT (author est.) with net cash, optional HK relist. AV risk mitigated near term by labor/regs; Didi can “platform” third-party AVs if/when economics flip.

BSD Analysis:
Resilient network effects (rider/driver density), improving take-rate/marketing normalization, and cost discipline support EBITA lift; risks: China policy, AMAP aggregation pressure, AV disintermediation, FX in LATAM, and “Other initiatives” cash burn. HK listing could broaden ownership.